Ulcerative Colitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | AbbVie, Boehringer, Eli Lilly and Company, Janssen, Mesoblast, Pfizer

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast

Some of the key facts of the Ulcerative Colitis Market Report: 

• The Ulcerative Colitis market size was approximately USD 6,900 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• A Totoal of 2,223,000 people with Ulcerative Colitis were prevalent overall in the 7MM in 2022. During the prediction period (from 2023 to 2032), these cases are anticipated to increase
• In the year 2022, the United States recorded the greatest prevalence of Ulcerative Colitis cases in the 7MM, with 1,026,000 cases, or roughly 46% of all cases
• The country with the most cases of UC among the EU4 and the UK had 357,000 cases in 2022
• The age range 18–44 years had the highest percentage of diagnosed Ulcerative Colitis cases (7MM), followed by 45–64 years (28%) and then 65–84 years (11%) and 85 years (1%), in 2022
• In 2022, there were 740,000 diagnosed prevalent cases and 1,024,000 prevalent cases of UC combined in EU4 and the UK
• Key Ulcerative Colitis Companies: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharmaceuticals, Arena, Protagonist Therapeutics, Palatin Technologies, Inc, Eli Lilly and Company, Pfizer, Janssen Research, Amgen, AbbVie, Landos Biopharma, Ferring Pharma, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma, EA Pharma, Prometheus Biosciences, and others
• Key Ulcerative Colitis Therapies: isankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Remestemcel-L, Corbitolimod, Etrasimod (APD334), PN-943, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, PRA023 IV, and others
• The Ulcerative Colitis epidemiology based on gender analyzed that moderate-to-severe UC cases accounts for ~55% of the total cases and the rest of the cases falls under mild category
• The Ulcerative Colitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

Ulcerative Colitis Overview

Inflammation and ulcers on the inner lining of your large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis. Although ulcerative colitis can occur at any age, those between the ages of 15 and 30 have the highest risk of developing the condition.

Get a Free sample for the Ulcerative Colitis Market Report 

https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market

Ulcerative Colitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ulcerative Colitis Epidemiology Segmentation:

The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Ulcerative Colitis
• Prevalent Cases of Ulcerative Colitis by severity
• Gender-specific Prevalence of Ulcerative Colitis
• Diagnosed Cases of Episodic and Chronic Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ulcerative Colitis Therapies and Key Companies

• Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
• Mirikizumab (LY3074828): Eli Lilly and Company
• Tremfya (Guselkumab): Janssen
• Remestemcel-L: Mesoblast Ltd.
• Corbitolimod: InDex Pharmaceuticals
• Etrasimod (APD334): Arena
• PN-943: Protagonist Therapeutics

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Market

Ulcerative Colitis Market Strengths

• With the market dynamics shifting towards medications with oral ROA, emergence of therapies like, BT-11,AJM300, Etrasimod, and SHR0302 will further drive the UC therapeutic market.
• Robust emerging pipeline with novel MOAs with less immunogenicity such as cobitolimod, BBT-401,Omilancor, and others are likely to strengthen the market.

Ulcerative Colitis Market Opportunities

• There lies tremendous potential in the UC landscape for drugs with better clinical profile especially in terms of safety. Safety concerns associated with JAK inhibitors poses a great opportunity for pharmaceutical companies to work on this front and improve the safety profile of upcoming drugs.
• Limited treatment options available in case of relapsed or refractory pool, provides lucrative opportunities in the UC therapeutic space.

Scope of the Ulcerative Colitis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mesoblast Ltd., InDex Pharmaceuticals, Arena, Protagonist Therapeutics, Palatin Technologies, Inc, Eli Lilly and Company, Pfizer, Janssen Research, Amgen, AbbVie, Landos Biopharma, Ferring Pharma, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma, EA Pharma, Prometheus Biosciences, and others
• Key Ulcerative Colitis Therapies: isankizumab (ABBV-066), Mirikizumab (LY3074828), Tremfya (Guselkumab), Remestemcel-L, Corbitolimod, Etrasimod (APD334), PN-943, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, PRA023 IV, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Ulcerative Colitis Unmet Needs, KOL’s views, Analyst’s views, Ulcerative Colitis Market Access and Reimbursement 

To know more about Ulcerative Colitis companies working in the treatment market, visit @ Ulcerative Colitis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Ulcerative Colitis Market Report Introduction

2. Executive Summary for Ulcerative Colitis

3. SWOT analysis of Ulcerative Colitis

4. Ulcerative Colitis Patient Share (%) Overview at a Glance

5. Ulcerative Colitis Market Overview at a Glance

6. Ulcerative Colitis Disease Background and Overview

7. Ulcerative Colitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Ulcerative Colitis 

9. Ulcerative Colitis Current Treatment and Medical Practices

10. Ulcerative Colitis Unmet Needs

11. Ulcerative Colitis Emerging Therapies

12. Ulcerative Colitis Market Outlook

13. Country-Wise Ulcerative Colitis Market Analysis (2019–2032)

14. Ulcerative Colitis Market Access and Reimbursement of Therapies

15. Ulcerative Colitis Market Drivers

16. Ulcerative Colitis Market Barriers

17.  Ulcerative Colitis Appendix

18. Ulcerative Colitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services